{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:57:05Z","timestamp":1781542625655,"version":"3.54.5"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Digit. Health"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Digital health technologies (DHTs) have the potential to alleviate challenges experienced in clinical trials through more objective, naturalistic, and frequent assessments of functioning. However, implementation of DHTs come with their own challenges, including acceptability and ease of use for study participants. In addition to acceptability, it is also important to understand device proficiency in the general population and within patient populations who may be asked to use DHTs for extended periods of time. We thus aimed to provide an overview of participant feedback on acceptability of DHTs, including body-worn sensors used in the clinic and a mobile application used at-home, used throughout the duration of the Wearable Assessments in the Clinic and at Home in Parkinson's Disease (WATCH-PD) study, an observational, longitudinal study looking at disease progression in early Parkinson's Disease (PD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>82 participants with PD and 50 control participants were enrolled at 17 sites throughout the United States and followed for 12 months. We assessed participants' general device proficiency at baseline, using the Mobile Device Proficiency Questionnaire (MDPQ). The mean MDPQ score at Baseline did not significantly differ between PD patients and healthy controls (20.6 [2.91] vs 21.5 [2.94], <jats:italic>p<\/jats:italic> = .10).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Questionnaire results demonstrated that participants had generally positive views on the comfort and use of the digital technologies throughout the duration of the study, regardless of group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This is the first study to evaluate patient feedback and impressions of using technology in a longitudinal observational study in early Parkinson's Disease. Results demonstrate device proficiency and acceptability of various DHTs in people with Parkinson's does not differ from that of neurologically healthy older adults, and, overall, participants had a favorable view of the DHTs deployed in the WATCH-PD study.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fdgth.2024.1435693","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T05:10:18Z","timestamp":1724649018000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Acceptability of digital health technologies in early Parkinson's disease: lessons from WATCH-PD"],"prefix":"10.3389","volume":"6","author":[{"given":"T.","family":"Kangarloo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. D.","family":"Latzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dorsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kostrzebski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Severson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Horak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"key":"B1","volume-title":"Mobile Fact Sheet","author":"Sidoti","year":"2024"},{"key":"B2","volume-title":"About One-in-Five Americans Use a Smart Watch or Fitness Tracker","author":"Vogels","year":"2020"},{"key":"B3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41746-019-0203-0","article-title":"Digital clinical trials: creating a vision for the future","volume":"2","author":"Steinhubl","year":"2019","journal-title":"NPJ Digital Medicine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41531-023-00497-x","article-title":"Using a smartwatch and smartphone to assess early Parkinson\u2019s disease in the WATCH-PD study","volume":"9","author":"Adams","year":"2023","journal-title":"NPJ Parkinson\u2019s Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41746-019-0123-z","article-title":"Harnessing digital technology to predict, diagnose, monitor, and develop treatments for brain disorders","volume":"2","author":"Stroud","year":"2019","journal-title":"NPJ Digit Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.2196\/mental.5165","article-title":"New tools for new research in psychiatry: a scalable and customizable platform to empower data driven smartphone research","volume":"3","author":"Torous","year":"2016","journal-title":"JMIR Ment Health"},{"key":"B7","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.3233\/jpd-202428","article-title":"Digital progression biomarkers as novel endpoints in clinical trials: a multistakeholder perspective","volume":"11","author":"Stephenson","year":"2021","journal-title":"J Parkinson\u2019s Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s43856-024-00481-3","article-title":"Improved measurement of disease progression in people living with early Parkinson\u2019s disease using digital health technologies","volume":"4","author":"Czech","year":"2024","journal-title":"Commun Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e0138095","DOI":"10.1371\/journal.pone.0138095","article-title":"Use of high-frequency in-home monitoring data may reduce sample sizes needed in clinical trials","volume":"10","author":"Dodge","year":"2015","journal-title":"PloS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41746-021-00473-w","article-title":"Empowering clinical research in a decentralized world","volume":"4","author":"Brouwer","year":"2021","journal-title":"npj Digit Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1038\/s41591-023-02391-8","article-title":"Digital health for aging populations","volume":"29","author":"Chen","year":"2023","journal-title":"Nat Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3109\/02703181.2014.946640","article-title":"Technology use by older adults and barriers to using technology","volume":"32","author":"Gitlow","year":"2014","journal-title":"Phys Occup Ther Geriatr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e39890","DOI":"10.2196\/39890","article-title":"The factors influencing older Adults\u2019 decisions surrounding adoption of technology: quantitative experimental study","volume":"5","author":"Moxley","year":"2022","journal-title":"JMIR Aging"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/S0140-6736(04)16305-8","article-title":"Parkinson's disease","volume":"363","author":"Samii","year":"2004","journal-title":"Lancet (London, England)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.14108","volume":"27","author":"Balestrino","year":"2020","journal-title":"Parkinson diseaseEur J Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3233\/JPD-202346","article-title":"People with Parkinson's disease: what symptoms do they most want to improve and how does this change with disease duration?","volume":"11","author":"Port","year":"2021","journal-title":"J Parkinsons Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement disorder society-sponsored revision of the unified Parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"B18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000477383","article-title":"The first frontier: digital biomarkers for neurodegenerative disorders","volume":"1","author":"Dorsey","year":"2017","journal-title":"Digit Biomark."},{"key":"B19","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/mds.27361","article-title":"Longitudinal change of clinical and biological measures in early Parkinson\u2019s disease: parkinson\u2019s progression markers initiative cohort","volume":"33","author":"Simuni","year":"2018","journal-title":"Mov Disord"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1007\/s13311-020-00960-0","article-title":"Overcoming barriers to Parkinson disease trial participation: increasing diversity and novel designs for recruitment and retention","volume":"17","author":"Vaswani","year":"2020","journal-title":"Neurotherapeutics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/0733464816642582","article-title":"A new tool for assessing Mobile device proficiency in older adults: the Mobile device proficiency questionnaire","volume":"37","author":"Roque","year":"2018","journal-title":"J Appl Gerontol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","article-title":"The Parkinson progression marker initiative (PPMI)","volume":"95","author":"Marek","year":"2011","journal-title":"Biol Mark Neurodegenerative Dis"}],"container-title":["Frontiers in Digital Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2024.1435693\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T05:10:21Z","timestamp":1724649021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2024.1435693\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":22,"alternative-id":["10.3389\/fdgth.2024.1435693"],"URL":"https:\/\/doi.org\/10.3389\/fdgth.2024.1435693","relation":{},"ISSN":["2673-253X"],"issn-type":[{"value":"2673-253X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,26]]},"article-number":"1435693"}}